OncoSec Medical Incorporated (ONCSQ)
Market Cap | 596.00 |
Revenue (ttm) | n/a |
Net Income (ttm) | -29.39M |
Shares Out | 5.96M |
EPS (ttm) | -15.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20,275 |
Open | n/a |
Previous Close | 0.0001 |
Day's Range | n/a |
52-Week Range | n/a |
Beta | -17.99 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About ONCSQ
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatme... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/p/a/press17-1898312.jpg)
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EWING, N.J. and SAN DIEGO , May 18, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immuno...
![](https://cdn.snapi.dev/images/v1/j/n/press1-1892947.jpg)
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EWING, N.J. and SAN DIEGO , May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immuno...
![](https://cdn.snapi.dev/images/v1/l/x/press4-1892029.jpg)
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
EWING, N.J. and SAN DIEGO , May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunother...
![](https://cdn.snapi.dev/images/v1/x/v/press19-1857448.jpg)
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
EWING, N.J. and SAN DIEGO , April 27, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunoth...
![](https://cdn.snapi.dev/images/v1/x/w/press20-1833083.jpg)
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EWING, N.J. and SAN DIEGO , April 11, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immu...
![](https://cdn.snapi.dev/images/v1/r/b/press3-1831043.jpg)
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EWING, N.J. and SAN DIEGO , April 10, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immu...
![](https://cdn.snapi.dev/images/v1/y/f/press9-1822675.jpg)
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
EWING, N.J. and SAN DIEGO , April 3, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunothe...
![](https://cdn.snapi.dev/images/v1/c/3/conf15-1662420.jpg)
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
PENNINGTON, N.J. and SAN DIEGO , Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
![](https://cdn.snapi.dev/images/v1/a/c/press8-1656495.jpg)
OncoSec Announces Pricing of $3.5 Million Public Offering
PENNINGTON, N.J. and SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing in...
![](https://cdn.snapi.dev/images/v1/8/h/press15-1638770.jpg)
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
PENNINGTON, N.J. and SAN DIEGO , Nov. 15, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral ...
![](https://cdn.snapi.dev/images/v1/7/4/press3-1632523.jpg)
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
PENNINGTON, N.J. and SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral ...
![](https://cdn.snapi.dev/images/v1/3/m/press14-1625618.jpg)
OncoSec Announces Reverse Stock Split
PENNINGTON, N.J. and SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
![](https://cdn.snapi.dev/images/v1/a/z/press1-1569480.jpg)
OncoSec Announces Pipeline Prioritization and Workforce Reduction
PENNINGTON, N.J. and SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
![](https://cdn.snapi.dev/images/v1/z/f/press11-1428424.jpg)
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO , June 24, 2022 /PRNewswire/ -- OncoSec Medical Incorporated ...
![](https://cdn.snapi.dev/images/v1/i/z/press4-1385902.jpg)
OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research
PENNINGTON, N.J. and SAN DIEGO , May 23, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Awa...
![](https://cdn.snapi.dev/images/v1/p/r/press2-1345057.jpg)
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
PENNINGTON, N.J. and SAN DIEGO , April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing i...
![](https://cdn.snapi.dev/images/v1/3/o/press14-1245380.jpg)
OncoSec Announces Appointment of George Chi as Chief Financial Officer
PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
![](https://cdn.snapi.dev/images/v1/f/m/press17-1155081.jpg)
OncoSec Announces Changes to its Board of Directors
PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cyt...
![](https://cdn.snapi.dev/images/v1/t/i/press16-1081345.jpg)
OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study
PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:...
![](https://cdn.snapi.dev/images/v1/a/u/press12-1058739.jpg)
OncoSec Provides Business Update
PENNINGTON, N.J. and SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cyt...
![](https://cdn.snapi.dev/images/v1/6/y/press18-967173.jpg)
OncoSec Provides Leadership Update
PENNINGTON, N.J. and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consis...
![](https://cdn.snapi.dev/images/v1/z/6/press7-924766.jpg)
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Bria...
Why Shares Of OncoSec Medical Are Trading Higher Today
OncoSec Medical (NASDAQ: ONCS) shares are trading higher after the company announced it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoS...
![](https://cdn.snapi.dev/images/v1/h/e/press7-896076.jpg)
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
PENNINGTON, N.J. and SAN DIEGO, July 6, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration ...
![](https://cdn.snapi.dev/images/v1/w/h/press4-882588.jpg)
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian L...